Picture loading failed.

Anti-PTPRC therapeutic antibody (Pre-made Apamistamab biosimilar,Whole mAb Radiolabelled) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. ... It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-029-1mg 1mg 3090
GMP-Bios-ab-029-10mg 10mg 21890
GMP-Bios-ab-029-100mg 100mg 148000
GMP-Bios-ab-029-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PTPRC therapeutic antibody (Pre-made Apamistamab biosimilar,Whole mAb Radiolabelled)
INN Name Apamistamab
TargetPTPRC
FormatWhole mAb Radiolabelled
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesActinium Pharmaceuticals;Fred Hutchinson Cancer Research Center
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma
Conditions DiscontinuedHodgkin's disease;Non-Hodgkin's lymphoma
Development Techna